The global drug-eluting stents market has seen healthy growth over the last few years with the help of technological developments and rising prevalence of cardiovascular diseases. Drug-eluting stents are designed to provide medication to prevent artery blockage following angioplasty with improved results than traditional stents. The market is developing on the strength of rising demands for low intervention, rising population ages, and growing awareness about cardiovascular diseases.
The major growth drivers to the DES market are technological advancements in the form of discovery of newer and better drugs and stent material that enhance biocompatibility along with the life of the device. In addition, the increase in the incidence rate of cardiovascular disease, particularly in developing nations, is fueling demand for the same.
Government programs and policies to support reimbursement of cardiovascular treatment also continue to be the pre-eminent driving force driving the growth in the market. Further, increase in demand for minimally invasive interventions and application of interventional cardiology treatment are the top drivers to growth of the market.
Despite these drivers, high expense of drug-eluting stents and side-effects due to potential conditions such as restenosis and thrombosis can be potential growth restraints for the market. Nevertheless, R&D activities are anticipated to nullify the challenges, propelling growth even for subsequent years or so.
Drug-eluting stents (DES) are sophisticated medical devices used in the treatment of coronary artery disease (CAD). The stents, usually metal mesh, have medication coated on them that slowly releases drugs to prevent re-blockage of the artery after the angioplasty has been done to open the artery.
The drug prevents the growth of scar tissue, which is one of the major causes of restenosis (re-blocking). DES has greatly enhanced patient outcomes with less likelihood of revascularization procedures compared to bare-metal stents (BMS).
The use of DES has increased manifold over the last few years due to technological advancements, growing cardiovascular awareness, and rising incidence of heart disease among the elderly population. Moreover, ongoing innovation in novel polymers and drug-delivery technologies has improved the performance, safety, and biocompatibility of stents. This, in turn, has resulted in the growing use of DES in developed as well as emerging economies.
However, the market is facing challenges such as costly treatment and potential long-term complications, including stent thrombosis, which require careful treatment of the patient. However, studies regarding second-generation DES and drug combinations are ongoing, set to reverse such challenges and maintain market growth. Demand for DES will remain high as cardiovascular disease spreads across the world.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
The drug-eluting stents (DES) market is developing at a historic rate with new drug-eluting stents launching into the market. The latest stents are aiming at the patient's result by releasing the drugs inside the arterial walls itself to prevent effectively restenosis (re-narrowing of the arteries) from the conventional bare-metal stents.
Evolving with drug delivery, polymer science, and stent technology, they have achieved increased biocompatibility and greater efficacy for which, increasingly, they are utilized to treat coronary artery disease. In addition, the increasing incidence of cardiovascular diseases and the aged population are inducing increasing demand for minimally invasive treatment.
Apart from the enhanced safety profile, the next-generation DES reduce repeat procedure needs, which is one of the main concerns for both - patients and healthcare systems. In addition, continuous R&D activities are introducing next-generation stents with biodegradable platforms and sophisticated drug delivery systems in the market and thereby driving the growth of the market.
With more numbers of healthcare experts embracing such fresh technology, the drug-eluting stents market will be expanding based on enhanced patient care as well as lower long-term healthcare costs. Together, DES development marks an extensive realignment of cardiovascular therapy protocols.
The market for Drug-Eluting Stents (DES) significantly influenced by the increasing incidence of cardiovascular diseases (CVDs) worldwide. CVDs such as coronary artery disease, heart attack, and stroke are leading causes of death and disability. The increasing incidence attributed to increasing population aging, physical inactivity, unhealthy diet, and high diabetes and hypertension rates.
As more and more individuals are diagnosed with CVDs, it becomes a higher priority to have proper treatment methods in place, such as drug-eluting stents. Next-generation DES provide a pioneering answer by inhibiting restenosis risk and providing enhanced long-term survival among patients undergoing percutaneous coronary intervention.
Drug release by the drugs therapeutically applied against stents causes growth suppression in cells, and consequently, constricting of the artery following the intervention. Enhanced understanding of CVD risk factors and benefits attained through premature intervention has seen enhanced adoption rate of DES use in clinical practices.
As healthcare systems try to take greater control of cardiovascular disease's burden, the drug-eluting stents market will keep growing. Growth is being driven by demand for new, less-invasive therapies that can enhance patients' quality of life and reduce the cost to the health care system of repeated cardiovascular events.
The polymer material segment dominates the global drug-eluting stents (DES) market due to its additional advantage and versatility of improving stent performance. Polymers play an important role in drug-eluting stents as they are used as drug carriers for therapeutic agents, regulating the rate of release of the drugs and providing local delivery to the arterial wall. Controlled release prevents restenosis risk and extends the duration of effective treatment.
In addition, advances in polymer technology have also brought forth biocompatible and biodegradable materials that facilitate enhanced patient outcome and late complications. Biodegradable polymers, for instance, erode gradually in the body and thus do away with the requirement of long-term anti-platelet therapy along with intolerance reactions towards permanent implantation.
Moreover, the plasticity and malleability of polymer materials allow for the design of stents with enhanced capability to track complex vascular geometries. This plasticity is vital to be realized in the effective implementation of successful clinical cases across a broad clinical range.
With the ever-increasing added need for superior, patient-specific cardiovascular interventions, the most recent innovations in polymer material field work to the benefit of the company to emerge as the market leader in the world in drug-eluting stents space and as part of today's cardiovascular intervention.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest analysis of the drug-eluting stents market, North America held the largest market share in 2024, driven by several key factors. North America leads the world in the drug-eluting stents (DES) market in terms of innovation.
Moreover, cardiovascular disease coupled with the aging population has led to an abrupt rise in demand for efficient solutions. North America possesses a highly developed healthcare system, which provides for broad availability of very advanced medical technologies like DES.
Besides, huge R&D investments by leading regional players in the medical devices sector have resulted in stent design and drug delivery new innovations. They improve the effectiveness and safety of DES, so they are compelling for doctors as well as patients. Furthermore, North America's regulatory culture ensures the most effective and best products reaching the market, also ensuring confidence among such products.
In addition, the presence of well-established healthcare facilities and high levels of health insurance coverage help to implement better medical technologies. Since patients as well as clinicians are interested in implementing minimal invasive procedures with better outcomes, drug-eluting stents keep growing in usage.
Abbott Laboratories, AlviMedica, B. Braun Melsungen AG, Biosensors International Group, Ltd., Shandong JW Medical Systems LTD., Boston Scientific Corporation, Cook Medical Inc., Elixir Medical Corp., Lepu Medical Technology (Beijing) Co., Ltd., Medtronic plc, Eurocor GmbH, OrbusNeich Medical Company Limited, Shanghai MicroPort Medical Co., Ltd., Sino Medical Sciences Technology Inc. are some of the leading players operating in the drug-eluting stents industry.
Each of these players have been have been profiled in the drug-eluting stents market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2024 | US$ 7.7 Bn |
| Forecast Value in 2035 | US$ 14.2 Bn |
| CAGR | 5.7% |
| Forecast Period | 2025-2035 |
| Historical Data Available for | 2020-2024 |
| Quantitative Units | US$ Bn |
| Drug-Eluting Stents Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global drug-eluting stents market was valued at US$ 7.7 Bn in 2024.
The drug-eluting stents business was projected to cross US$ 14.2 Bn by the end of 2035.
Introduction of advanced drug eluting stent along with increasing prevalence of cardiovascular disease are driving the drug-eluting stents market.
It is projected to advance at a CAGR of 5.7% from 2025 to 2035.
North America was the dominant region in 2024.
Abbott Laboratories, AlviMedica, B. Braun Melsungen AG, Biosensors International Group, Ltd., Shandong JW Medical Systems LTD., Boston Scientific Corporation, Cook Medical Inc., Elixir Medical Corp., Lepu Medical Technology (Beijing) Co., Ltd., Medtronic plc, Eurocor GmbH, OrbusNeich Medical Company Limited, Shanghai MicroPort Medical Co., Ltd., Sino Medical Sciences Technology Inc., and others.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Drug-Eluting Stents Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Drug-Eluting Stents Market Analysis and Forecast, 2020-2035
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Technological Advancements
5.2. PORTER’s Five Forces Analysis
5.3. PESTEL Analysis
5.4. Supply Chain Analysis
5.5. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
5.6. Pricing Analysis (Brand pricing, Average Selling Price by Region/Country)
5.7. Regulatory Scenario by Key Country/Region
5.8. Research and Development Trends
5.9. Go-to-Market Strategy for New Market Entrants
6. Global Drug-Eluting Stents Market Analysis and Forecast, by Material
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Material, 2020-2035
6.3.1. Metal
6.3.1.1. Stainless-Steel
6.3.1.2. Cobalt-Chromium
6.3.1.3. Nitinol
6.3.1.4. Others
6.3.2. Polymer
6.3.2.1. Non-biodegradable Polymers
6.3.2.2. Biodegradable Polymers
6.4. Market Attractiveness Analysis, by Material
7. Global Drug-Eluting Stents Market Analysis and Forecast, by Drug
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug, 2020-2035
7.3.1. Sirolimus
7.3.2. Paclitaxel
7.3.3. Zotarolimus
7.3.4. Everolimus
7.3.5. Others
7.4. Market Attractiveness Analysis, by Drug
8. Global Drug-Eluting Stents Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application , 2020-2035
8.3.1. Coronary Artery Disease
8.3.2. Peripheral Artery Disease
8.3.3. Others
8.4. Market Attractiveness Analysis, by Application
9. Global Drug-Eluting Stents Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2035
9.3.1. Hospitals
9.3.2. Ambulatory Surgical Centers
9.3.3. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Drug-Eluting Stents Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2035
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Region
11. North America Drug-Eluting Stents Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Material, 2020-2035
11.2.1. Metal
11.2.1.1. Stainless-Steel
11.2.1.2. Cobalt-Chromium
11.2.1.3. Nitinol
11.2.1.4. Others
11.2.2. Polymer
11.2.2.1. Non-biodegradable Polymers
11.2.2.2. Biodegradable Polymers
11.3. Market Value Forecast, by Drug, 2020-2035
11.3.1. Sirolimus
11.3.2. Paclitaxel
11.3.3. Zotarolimus
11.3.4. Everolimus
11.3.5. Others
11.4. Market Value Forecast, by Application , 2020-2035
11.4.1. Coronary Artery Disease
11.4.2. Peripheral Artery Disease
11.4.3. Others
11.5. Market Value Forecast, by End-user, 2020-2035
11.5.1. Hospitals
11.5.2. Ambulatory Surgical Centers
11.5.3. Others
11.6. Market Value Forecast, by Country, 2020-2035
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Material
11.7.2. By Drug
11.7.3. By Application
11.7.4. By End-user
11.7.5. By Country
12. Europe Drug-Eluting Stents Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Material, 2020-2035
12.2.1. Metal
12.2.1.1. Stainless-Steel
12.2.1.2. Cobalt-Chromium
12.2.1.3. Nitinol
12.2.1.4. Others
12.2.2. Polymer
12.2.2.1. Non-biodegradable Polymers
12.2.2.2. Biodegradable Polymers
12.3. Market Value Forecast, by Drug, 2020-2035
12.3.1. Sirolimus
12.3.2. Paclitaxel
12.3.3. Zotarolimus
12.3.4. Everolimus
12.3.5. Others
12.4. Market Value Forecast, by Application , 2020-2035
12.4.1. Coronary Artery Disease
12.4.2. Peripheral Artery Disease
12.4.3. Others
12.5. Market Value Forecast, by End-user, 2020-2035
12.5.1. Hospitals
12.5.2. Ambulatory Surgical Centers
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2020-2035
12.6.1. Germany
12.6.2. UK
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Material
12.7.2. By Drug
12.7.3. By Application
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Drug-Eluting Stents Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Material, 2020-2035
13.2.1. Metal
13.2.1.1. Stainless-Steel
13.2.1.2. Cobalt-Chromium
13.2.1.3. Nitinol
13.2.1.4. Others
13.2.2. Polymer
13.2.2.1. Non-biodegradable Polymers
13.2.2.2. Biodegradable Polymers
13.3. Market Value Forecast, by Drug, 2020-2035
13.3.1. Sirolimus
13.3.2. Paclitaxel
13.3.3. Zotarolimus
13.3.4. Everolimus
13.3.5. Others
13.4. Market Value Forecast, by Application , 2020-2035
13.4.1. Coronary Artery Disease
13.4.2. Peripheral Artery Disease
13.4.3. Others
13.5. Market Value Forecast, by End-user, 2020-2035
13.5.1. Hospitals
13.5.2. Ambulatory Surgical Centers
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2020-2035
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Material
13.7.2. By Drug
13.7.3. By Application
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Drug-Eluting Stents Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Material, 2020-2035
14.2.1. Metal
14.2.1.1. Stainless-Steel
14.2.1.2. Cobalt-Chromium
14.2.1.3. Nitinol
14.2.1.4. Others
14.2.2. Polymer
14.2.2.1. Non-biodegradable Polymers
14.2.2.2. Biodegradable Polymers
14.3. Market Value Forecast, by Drug, 2020-2035
14.3.1. Sirolimus
14.3.2. Paclitaxel
14.3.3. Zotarolimus
14.3.4. Everolimus
14.3.5. Others
14.4. Market Value Forecast, by Application , 2020-2035
14.4.1. Coronary Artery Disease
14.4.2. Peripheral Artery Disease
14.4.3. Others
14.5. Market Value Forecast, by End-user, 2020-2035
14.5.1. Hospitals
14.5.2. Ambulatory Surgical Centers
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2020-2035
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Material
14.7.2. By Drug
14.7.3. By Application
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Drug-Eluting Stents Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Material, 2020-2035
15.2.1. Metal
15.2.1.1. Stainless-Steel
15.2.1.2. Cobalt-Chromium
15.2.1.3. Nitinol
15.2.1.4. Others
15.2.2. Polymer
15.2.2.1. Non-biodegradable Polymers
15.2.2.2. Biodegradable Polymers
15.3. Market Value Forecast, by Drug, 2020-2035
15.3.1. Sirolimus
15.3.2. Paclitaxel
15.3.3. Zotarolimus
15.3.4. Everolimus
15.3.5. Others
15.4. Market Value Forecast, by Application , 2020-2035
15.4.1. Coronary Artery Disease
15.4.2. Peripheral Artery Disease
15.4.3. Others
15.5. Market Value Forecast, by End-user, 2020-2035
15.5.1. Hospitals
15.5.2. Ambulatory Surgical Centers
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2020-2035
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Material
15.7.2. By Drug
15.7.3. By Application
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2024)
16.3. Company Profiles
16.3.1. Abbott Laboratories
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategies
16.3.1.5. Recent Developments
16.3.2. AlviMedica
16.3.2.1. Company Overview
16.3.2.2. Financial Overview
16.3.2.3. Product Portfolio
16.3.2.4. Business Strategies
16.3.2.5. Recent Developments
16.3.3. B. Braun Melsungen AG
16.3.3.1. Company Overview
16.3.3.2. Financial Overview
16.3.3.3. Product Portfolio
16.3.3.4. Business Strategies
16.3.3.5. Recent Developments
16.3.4. Biosensors International Group, Ltd.
16.3.4.1. Company Overview
16.3.4.2. Financial Overview
16.3.4.3. Product Portfolio
16.3.4.4. Business Strategies
16.3.4.5. Recent Developments
16.3.5. Shandong JW Medical Systems LTD.
16.3.5.1. Company Overview
16.3.5.2. Financial Overview
16.3.5.3. Product Portfolio
16.3.5.4. Business Strategies
16.3.5.5. Recent Developments
16.3.6. Boston Scientific Corporation
16.3.6.1. Company Overview
16.3.6.2. Financial Overview
16.3.6.3. Product Portfolio
16.3.6.4. Business Strategies
16.3.6.5. Recent Developments
16.3.7. Cook Medical Inc.
16.3.7.1. Company Overview
16.3.7.2. Financial Overview
16.3.7.3. Product Portfolio
16.3.7.4. Business Strategies
16.3.7.5. Recent Developments
16.3.8. Elixir Medical Corp.
16.3.8.1. Company Overview
16.3.8.2. Financial Overview
16.3.8.3. Product Portfolio
16.3.8.4. Business Strategies
16.3.8.5. Recent Developments
16.3.9. Lepu Medical Technology (Beijing) Co., Ltd.
16.3.9.1. Company Overview
16.3.9.2. Financial Overview
16.3.9.3. Product Portfolio
16.3.9.4. Business Strategies
16.3.9.5. Recent Developments
16.3.10. Medtronic plc
16.3.10.1. Company Overview
16.3.10.2. Financial Overview
16.3.10.3. Product Portfolio
16.3.10.4. Business Strategies
16.3.10.5. Recent Developments
16.3.11. Eurocor GmbH
16.3.11.1. Company Overview
16.3.11.2. Financial Overview
16.3.11.3. Product Portfolio
16.3.11.4. Business Strategies
16.3.11.5. Recent Developments
16.3.12. OrbusNeich Medical Company Limited
16.3.12.1. Company Overview
16.3.12.2. Financial Overview
16.3.12.3. Product Portfolio
16.3.12.4. Business Strategies
16.3.12.5. Recent Developments
16.3.13. Shanghai MicroPort Medical Co., Ltd.
16.3.13.1. Company Overview
16.3.13.2. Financial Overview
16.3.13.3. Product Portfolio
16.3.13.4. Business Strategies
16.3.13.5. Recent Developments
16.3.14. Sino Medical Sciences Technology Inc.
16.3.14.1. Company Overview
16.3.14.2. Financial Overview
16.3.14.3. Product Portfolio
16.3.14.4. Business Strategies
16.3.14.5. Recent Developments
List of Tables
Table 01: Global Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Material, 2020-2035
Table 02: Global Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Metal, 2020-2035
Table 03: Global Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Polymer, 2020-2035
Table 04: Global Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Drug, 2020-2035
Table 05: Global Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Application, 2020-2035
Table 06: Global Drug-Eluting Stents Market Value (US$ Bn) Forecast, By End-user, 2020-2035
Table 07: Global Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Region, 2020-2035
Table 08: North America - Drug-Eluting Stents Market Value (US$ Bn) Forecast, by Country, 2020-2035
Table 09: North America - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Material, 2020-2035
Table 10: North America - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Metal, 2020-2035
Table 11: North America - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Polymer, 2020-2035
Table 12: North America - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Drug, 2020-2035
Table 13: North America - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Application, 2020-2035
Table 14: North America - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By End-user, 2020-2035
Table 15: Europe - Drug-Eluting Stents Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 16: Europe - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Material, 2020-2035
Table 17: Europe - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Metal, 2020-2035
Table 18: Europe - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Polymer, 2020-2035
Table 19: Europe - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Drug, 2020-2035
Table 20: Europe - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Application, 2020-2035
Table 21: Europe - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By End-user, 2020-2035
Table 22: Asia Pacific - Drug-Eluting Stents Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 23: Asia Pacific - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Material, 2020-2035
Table 24: Asia Pacific - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Metal, 2020-2035
Table 25: Asia Pacific - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Polymer, 2020-2035
Table 26: Asia Pacific - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Drug, 2020-2035
Table 27: Asia Pacific - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Application, 2020-2035
Table 28: Asia Pacific - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By End-user, 2020-2035
Table 29: Latin America - Drug-Eluting Stents Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 30: Latin America - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Material, 2020-2035
Table 31: Latin America - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Metal, 2020-2035
Table 32: Latin America - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Polymer, 2020-2035
Table 33: Latin America - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Drug, 2020-2035
Table 34: Latin America - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Application, 2020-2035
Table 35: Latin America - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By End-user, 2020-2035
Table 36: Middle East & Africa - Drug-Eluting Stents Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020-2035
Table 37: Middle East & Africa - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Material, 2020-2035
Table 38: Middle East & Africa - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Metal, 2020-2035
Table 39: Middle East & Africa - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Polymer, 2020-2035
Table 40: Middle East & Africa - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Drug, 2020-2035
Table 41: Middle East & Africa - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By Application, 2020-2035
Table 42: Middle East & Africa - Drug-Eluting Stents Market Value (US$ Bn) Forecast, By End-user, 2020-2035
List of Figures
Figure 01: Global Drug-Eluting Stents Market Value (US$ Bn) Forecast, 2020-2035
Figure 02: Global Drug-Eluting Stents Market Value Share Analysis, By Material, 2024 and 2035
Figure 03: Global Drug-Eluting Stents Market Attractiveness Analysis, By Material, 2025-2035
Figure 04: Global Drug-Eluting Stents Market Revenue (US$ Bn), by Polymer, 2020-2035
Figure 05: Global Drug-Eluting Stents Market Revenue (US$ Bn), by Metal, 2020-2035
Figure 06: Global Drug-Eluting Stents Market Value Share Analysis, By Drug, 2024 and 2035
Figure 07: Global Drug-Eluting Stents Market Attractiveness Analysis, By Drug, 2025-2035
Figure 08: Global Drug-Eluting Stents Market Revenue (US$ Bn), by Sirolimus, 2020-2035
Figure 09: Global Drug-Eluting Stents Market Revenue (US$ Bn), by Paclitaxel, 2020-2035
Figure 10: Global Drug-Eluting Stents Market Revenue (US$ Bn), by Zotarolimus, 2020-2035
Figure 11: Global Drug-Eluting Stents Market Revenue (US$ Bn), by Everolimus, 2020-2035
Figure 12: Global Drug-Eluting Stents Market Revenue (US$ Bn), by Others, 2020-2035
Figure 13: Global Drug-Eluting Stents Market Value Share Analysis, By Application, 2024 and 2035
Figure 14: Global Drug-Eluting Stents Market Attractiveness Analysis, By Application, 2025-2035
Figure 15: Global Drug-Eluting Stents Market Revenue (US$ Bn), by Coronary Artery Disease, 2020-2035
Figure 16: Global Drug-Eluting Stents Market Revenue (US$ Bn), by Peripheral Artery Disease, 2020-2035
Figure 17: Global Drug-Eluting Stents Market Revenue (US$ Bn), by Others, 2020-2035
Figure 18: Global Drug-Eluting Stents Market Value Share Analysis, By End-user, 2024 and 2035
Figure 19: Global Drug-Eluting Stents Market Attractiveness Analysis, By End-user, 2025-2035
Figure 20: Global Drug-Eluting Stents Market Revenue (US$ Bn), by Hospital, 2020-2035
Figure 21: Global Drug-Eluting Stents Market Revenue (US$ Bn), by Ambulatory Surgical Centers, 2020-2035
Figure 22: Global Drug-Eluting Stents Market Revenue (US$ Bn), by Others, 2020-2035
Figure 23: Global Drug-Eluting Stents Market Value Share Analysis, By Region, 2024 and 2035
Figure 24: Global Drug-Eluting Stents Market Attractiveness Analysis, By Region, 2025-2035
Figure 25: North America - Drug-Eluting Stents Market Value (US$ Bn) Forecast, 2020-2035
Figure 26: North America - Drug-Eluting Stents Market Value Share Analysis, by Country, 2024 and 2035
Figure 27: North America - Drug-Eluting Stents Market Attractiveness Analysis, by Country, 2025-2035
Figure 28: North America - Drug-Eluting Stents Market Value Share Analysis, By Material, 2024 and 2035
Figure 29: North America - Drug-Eluting Stents Market Attractiveness Analysis, By Material, 2025-2035
Figure 30: North America - Drug-Eluting Stents Market Value Share Analysis, By Drug, 2024 and 2035
Figure 31: North America - Drug-Eluting Stents Market Attractiveness Analysis, By Drug, 2025-2035
Figure 32: North America - Drug-Eluting Stents Market Value Share Analysis, By Application, 2024 and 2035
Figure 33: North America - Drug-Eluting Stents Market Attractiveness Analysis, By Application, 2025-2035
Figure 34: North America - Drug-Eluting Stents Market Value Share Analysis, By End-user, 2024 and 2035
Figure 35: North America - Drug-Eluting Stents Market Attractiveness Analysis, By End-user, 2025-2035
Figure 36: Europe - Drug-Eluting Stents Market Value (US$ Bn) Forecast, 2020-2035
Figure 37: Europe - Drug-Eluting Stents Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 38: Europe - Drug-Eluting Stents Market Attractiveness Analysis, by Country / Sub-region, 2025-2035
Figure 39: Europe - Drug-Eluting Stents Market Value Share Analysis, By Material, 2024 and 2035
Figure 40: Europe - Drug-Eluting Stents Market Attractiveness Analysis, By Material, 2025-2035
Figure 41: Europe - Drug-Eluting Stents Market Value Share Analysis, By Drug, 2024 and 2035
Figure 42: Europe - Drug-Eluting Stents Market Attractiveness Analysis, By Drug, 2025-2035
Figure 43: Europe - Drug-Eluting Stents Market Value Share Analysis, By Application, 2024 and 2035
Figure 44: Europe - Drug-Eluting Stents Market Attractiveness Analysis, By Application, 2025-2035
Figure 45: Europe - Drug-Eluting Stents Market Value Share Analysis, By End-user, 2024 and 2035
Figure 46: Europe - Drug-Eluting Stents Market Attractiveness Analysis, By End-user, 2025-2035
Figure 47: Asia Pacific - Drug-Eluting Stents Market Value (US$ Bn) Forecast, 2020-2035
Figure 48: Asia Pacific - Drug-Eluting Stents Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 49: Asia Pacific - Drug-Eluting Stents Market Attractiveness Analysis, by Country/Sub-region, 2025-2035
Figure 50: Asia Pacific - Drug-Eluting Stents Market Value Share Analysis, By Material, 2024 and 2035
Figure 51: Asia Pacific - Drug-Eluting Stents Market Attractiveness Analysis, By Material, 2025-2035
Figure 52: Asia Pacific - Drug-Eluting Stents Market Value Share Analysis, By Drug, 2024 and 2035
Figure 53: Asia Pacific - Drug-Eluting Stents Market Attractiveness Analysis, By Drug, 2025-2035
Figure 54: Asia Pacific - Drug-Eluting Stents Market Value Share Analysis, By Application, 2024 and 2035
Figure 55: Asia Pacific - Drug-Eluting Stents Market Attractiveness Analysis, By Application, 2025-2035
Figure 56: Asia Pacific - Drug-Eluting Stents Market Value Share Analysis, By End-user, 2024 and 2035
Figure 57: Asia Pacific - Drug-Eluting Stents Market Attractiveness Analysis, By End-user, 2025-2035
Figure 58: Latin America - Drug-Eluting Stents Market Value (US$ Bn) Forecast, 2020-2035
Figure 59: Latin America - Drug-Eluting Stents Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 60: Latin America - Drug-Eluting Stents Market Attractiveness Analysis, by Country / Sub-region, 2025-2035
Figure 61: Latin America - Drug-Eluting Stents Market Value Share Analysis, By Material, 2024 and 2035
Figure 62: Latin America - Drug-Eluting Stents Market Attractiveness Analysis, By Material, 2025-2035
Figure 63: Latin America - Drug-Eluting Stents Market Value Share Analysis, By Drug, 2024 and 2035
Figure 64: Latin America - Drug-Eluting Stents Market Attractiveness Analysis, By Drug, 2025-2035
Figure 65: Latin America - Drug-Eluting Stents Market Value Share Analysis, By Application, 2024 and 2035
Figure 66: Latin America - Drug-Eluting Stents Market Attractiveness Analysis, By Application, 2025-2035
Figure 67: Latin America - Drug-Eluting Stents Market Value Share Analysis, By End-user, 2024 and 2035
Figure 68: Latin America - Drug-Eluting Stents Market Attractiveness Analysis, By End-user, 2025-2035
Figure 69: Middle East & Africa - Drug-Eluting Stents Market Value (US$ Bn) Forecast, 2020-2035
Figure 70: Middle East & Africa - Drug-Eluting Stents Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 71: Middle East & Africa - Drug-Eluting Stents Market Attractiveness Analysis, by Country / Sub-region, 2025-2035
Figure 72: Middle East & Africa - Drug-Eluting Stents Market Value Share Analysis, By Material, 2024 and 2035
Figure 73: Middle East & Africa - Drug-Eluting Stents Market Attractiveness Analysis, By Material, 2025-2035
Figure 74: Middle East & Africa - Drug-Eluting Stents Market Value Share Analysis, By Drug, 2024 and 2035
Figure 75: Middle East & Africa - Drug-Eluting Stents Market Attractiveness Analysis, By Drug, 2025-2035
Figure 76: Middle East & Africa - Drug-Eluting Stents Market Value Share Analysis, By Application, 2024 and 2035
Figure 77: Middle East & Africa - Drug-Eluting Stents Market Attractiveness Analysis, By Application, 2025-2035
Figure 78: Middle East & Africa - Drug-Eluting Stents Market Value Share Analysis, By End-user, 2024 and 2035
Figure 79: Middle East & Africa - Drug-Eluting Stents Market Attractiveness Analysis, By End-user, 2025-2035
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Drug-Eluting Stents Market
